Wuhan Hiteck Biological Pharma Co.,Ltd

Shenzhen Stock Exchange 300683.SZ

Wuhan Hiteck Biological Pharma Co.,Ltd Goodwill for the year ending December 31, 2023: USD 37.13 M

Wuhan Hiteck Biological Pharma Co.,Ltd Goodwill is USD 37.13 M for the year ending December 31, 2023, a -15.21% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Wuhan Hiteck Biological Pharma Co.,Ltd Goodwill for the year ending December 31, 2022 was USD 43.78 M, a -12.01% change year over year.
Wuhan Hiteck Biological Pharma Co.,Ltd Goodwill for the year ending December 31, 2021 was USD 49.76 M, a 2.64% change year over year.
Wuhan Hiteck Biological Pharma Co.,Ltd Goodwill for the year ending December 31, 2020 was USD 48.48 M, a 22.46% change year over year.
Wuhan Hiteck Biological Pharma Co.,Ltd Goodwill for the year ending December 31, 2019 was USD 39.59 M, a -1.14% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

Shenzhen Stock Exchange: 300683.SZ

Wuhan Hiteck Biological Pharma Co.,Ltd

CEO	Mr. Ya Chen
IPO Date	Aug. 8, 2017
Location	China
Headquarters	Hite Science and Technology Park
Employees	1,520
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Personal Care Plastics Vaccines

Description

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit. In addition, it offers Lopinavir and Ritonavir APIs; and intermediates. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.

Key trends

Past 5 years